Biotricity Reports Strong Q2 2025 Results, Highlighting AI-Driven Growth in Remote Cardiac Monitoring

Biotricity Reports Strong Q2 2025 Financial Performance

Biotricity Inc., a Technology-as-a-Service (TaaS) company specializing in remote cardiac monitoring, has announced positive financial results for the second quarter of fiscal year 2025. The company reported year-over-year revenue growth and improvements across key operating metrics, including recurring technology fees, device sales, and gross margins 1

1

.

Dr. Waqaas Al-Siddiq, Biotricity's Founder & CEO, emphasized the company's focus on automation, operational efficiency, and financial discipline. He stated, "Our primary focus remains on driving revenue and margins, and we were pleased to see these metrics trend upwards" 1

1

.

AI-Driven Advancements in Cardiac Care

Biotricity has made significant strides in leveraging artificial intelligence for cardiac care. The company's Cardiac AI cloud has recorded hundreds of billions of heartbeats, contributing to over 50,000 atrial fibrillation (Afib) diagnoses in the past two years 1

1

. This technology enables earlier medical intervention, potentially leading to substantial healthcare savings for patients and the overall healthcare system.

The company has expanded its AI technology development, focusing on creating predictive remote monitoring tools. These advancements aim to enhance disease profiling, improve patient management, and revolutionize disease prevention in remote cardiac care 1

1

.

Strategic Partnerships and Market Expansion

Biotricity has formed strategic alliances with top group purchasing organizations (GPOs) and specialist organizations in neurology and pulmonology. These partnerships have initiated multiple large-scale pilot programs and expanded the company's reach beyond cardiology, significantly increasing its market potential 2

2

.

Research and FDA Approval Plans

The company recently published research in Nature on predicting postoperative complications, showcasing its commitment to scientific advancement. Biotricity plans to expand its research efforts and file for FDA approval of its AI clinical model by mid-next year 2

2

.

Financial Milestones

In a significant development, Biotricity achieved positive EBITDA for the first time in September 2025, marking a crucial step towards profitability. The company attributes this success to improvements across all aspects of the business, including revenues, margins, and operational efficiency 2

2

.

Future Outlook

Biotricity remains focused on its mission to produce transformative healthcare technologies. The company continues to refine its suite of products and robust platform based on feedback from cardiologists and electrophysiologists. With its strong performance in Q2 2025, Biotricity is well-positioned to capitalize on the growing demand for remote cardiac monitoring solutions and AI-driven healthcare technologies.